Published Online
on January 24, 2005

A more recent version of this article appeared on February 8, 2005

This Article Full Text (PDF) All Versions of this Article: 111/5/591    most recent 01.CIR.0000142291.70954.DFv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tachibana, H. Articles by Rockman, H. A. Search for Related Content PubMed PubMed Citation Articles by Tachibana, H. Articles by Rockman, H. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Animal models of human disease Cell signalling/signal transduction Genetically altered mice Heart failure - basic studies Receptor pharmacology

Submitted on February 12, 2004
Revised on April 22, 2004
Accepted on May 19, 2004

Level of -Adrenergic Receptor Kinase 1 Inhibition Determines Degree of Cardiac Dysfunction After Chronic Pressure Overload-Induced Heart Failure

Hideo Tachibana MD, PhD, Sathyamangla V. Naga Prasad PhD, Robert J. Lefkowitz MD, Walter J. Koch PhD, and Howard A. Rockman MD^*

From the Departments of Medicine (H.T., S.V.N.P., R.J.L., H.A.R.), Cell Biology (H.A.R.), Molecular Genetics (H.A.R.), and Surgery (W.J.K.), and the Howard Hughes Medical Institute (R.J.L.), Duke University Medical Center, Durham, NC. Dr Koch is now at the Center for Translational Medicine, Jefferson Medical College, Philadelphia, Pa.

^* To whom correspondence should be addressed. E-mail: h.rockman{at}duke.edu.

Background--Heart failure is characterized by abnormalities in -adrenergic receptor (AR) signaling, including increased level of myocardial AR kinase 1 (ARK1). Our previous studies have shown that inhibition of ARK1 with the use of the G sequestering peptide of ARK1 (ARKct) can prevent cardiac dysfunction in models of heart failure. Because inhibition of ARK activity is pivotal for amelioration of cardiac dysfunction, we investigated whether the level of ARK1 inhibition correlates with the degree of heart failure.

Methods and Results--Transgenic (TG) mice with varying degrees of cardiac-specific expression of ARKct peptide underwent transverse aortic constriction (TAC) for 12 weeks. Cardiac function was assessed by serial echocardiography in conscious mice, and the level of myocardial ARKct protein was quantified at termination of the study. TG mice showed a positive linear relationship between the level of ARKct protein expression and fractional shortening at 12 weeks after TAC. TG mice with low ARKct expression developed severe heart failure, whereas mice with high ARKct expression showed significantly less cardiac deterioration than wild-type (WT) mice. Importantly, mice with a high level of ARKct expression had preserved isoproterenol-stimulated adenylyl cyclase activity and normal AR densities in the cardiac membranes. In contrast, mice with low expression of the transgene had marked abnormalities in AR function, similar to the WT mice.

Conclusions--These data show that the level of ARK1 inhibition determines the degree to which cardiac function can be preserved in response to pressure overload and has important therapeutic implications when ARK1 inhibition is considered as a molecular target.

Key words: receptors, adrenergic, beta • heart failure • signal transduction • mice, transgenic • gene therapy

This article has been cited by other articles:

				X. Loyer, A. M. Gomez, P. Milliez, M. Fernandez-Velasco, P. Vangheluwe, L. Vinet, D. Charue, E. Vaudin, W. Zhang, Y. Sainte-Marie, et al. Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling Circulation, June 24, 2008; 117(25): 3187 - 3198. [Abstract] [Full Text] [PDF]

				M. Endoh Novel signalling cascade for cardiac hypertrophy activation by uncoupling and internalization of {beta}1-adrenoceptors Cardiovasc Res, April 1, 2008; 78(1): 5 - 7. [Full Text] [PDF]

				C. Morisco, C. Marrone, J. Galeotti, D. Shao, D. E. Vatner, S. F. Vatner, and J. Sadoshima Endocytosis machinery is required for {beta}1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes Cardiovasc Res, April 1, 2008; 78(1): 36 - 44. [Abstract] [Full Text] [PDF]

				S. J. Matkovich, A. Diwan, J. L. Klanke, D. J. Hammer, Y. Marreez, A. M. Odley, E. W. Brunskill, W. J. Koch, R. J. Schwartz, and G. W. Dorn II Cardiac-Specific Ablation of G-Protein Receptor Kinase 2 Redefines Its Roles in Heart Development and {beta}-Adrenergic Signaling Circ. Res., October 27, 2006; 99(9): 996 - 1003. [Abstract] [Full Text] [PDF]

				A. Curcio, T. Noma, S. V. Naga Prasad, M. J. Wolf, A. Lemaire, C. Perrino, L. Mao, and H. A. Rockman Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1754 - H1760. [Abstract] [Full Text] [PDF]